Every material Form 8-K Corvus Pharmaceuticals, Inc. has filed with the SEC since July 22, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Corvus Pharmaceuticals reported a third-quarter 2026 net loss of $20.3 million, up from $10.2 million a year earlier, as research and development expenses rose to $17.8 million from $8.5 million. The company had $202.9 million in cash, cash equivalents and marketable securities at September 30, 2026, which it says will fund operations into the second quarter of 2028.
Q3 2026 net loss was $20.3 million, or $0.22 per share, versus $10.2 million, or $0.12 per share, in Q3 2025.
Research and development expenses were $17.8 million for the quarter, up $9.3 million, mainly from higher clinical trial costs for soquelitinib.
Cash, cash equivalents and marketable securities were $202.9 million at September 30, 2026, including about $189.4 million in net proceeds from a financing completed January 23, 2026.
The company said its cash is expected to fund operations into the second quarter of 2028.
Corvus Pharmaceuticals reported a second-quarter 2026 net loss of $18.0 million, up from $8.0 million a year earlier, as research and development expenses roughly doubled to $16.0 million. The company said its cash, cash equivalents and marketable securities of $215.2 million, up from $56.8 million at December 31, 2025, fund operations into the second quarter of 2028, and it reiterated enrollment in its Phase 3 and Phase 2 soquelitinib trials.
Q2 2026 net loss was $18.0 million, or $0.19 per share, versus $8.0 million, or $0.10 per share, in Q2 2025.
R&D expenses were $16.0 million for the quarter, up $8.1 million, mainly from higher clinical trial costs and personnel costs.
Cash, cash equivalents and marketable securities were $215.2 million at June 30, 2026, including about $189.4 million in net proceeds from a financing completed January 23, 2026.
The filing reports no revenue line for the quarter.
Corvus Pharmaceuticals said director Ian T. Clark gave notice on July 21, 2026 that he will resign from its board, effective July 22, 2026. The company thanked him for more than nine years of board service, and the filing gives no replacement or reason for the departure.
Ian T. Clark delivered resignation notice on July 21, 2026.
Resignation is effective July 22, 2026.
Clark served on the board for over nine years, according to the company.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Corvus Pharmaceuticals, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →